Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Alx Oncology Holdings (ALXO) Change in Acquisitions & Divestments (2022 - 2026)

Alx Oncology Holdings' Change in Acquisitions & Divestments history spans 2 years, with the latest figure at $58.5 million for Q4 2023.

On a quarterly basis, Change in Acquisitions & Divestments fell 19.1% to $58.5 million in Q4 2023 year-over-year; TTM through Dec 2023 was $292.6 million, a N/A change, with the full-year FY2025 number at $134.4 million, down 30.77% from a year prior.
Change in Acquisitions & Divestments hit $58.5 million in Q4 2023 for Alx Oncology Holdings, down from $64.4 million in the prior quarter.
Over the last five years, Change in Acquisitions & Divestments for ALXO hit a ceiling of $115.2 million in Q1 2023 and a floor of $50.5 million in Q3 2022.